公开(公告)号：US20240307380A1

公开(公告)日：2024-09-19

申请号：US18670637

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Joshua JORDAN ,  Adam SAVITZ

IPC: A61K31/496 ,  A61B5/16 ,  A61B5/374 ,  A61K9/00 ,  A61K31/19 ,  A61K31/53 ,  A61K33/00 ,  A61P25/24

CPC classification number: A61K31/496 ,  A61K9/0053 ,  A61K31/19 ,  A61K31/53 ,  A61K33/00 ,  A61P25/24 ,  A61B5/165 ,  A61B5/374

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20240307378A1

公开(公告)日：2024-09-19

申请号：US18670619

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Joshua JORDAN ,  Adam SAVITZ

IPC: A61K31/496 ,  A61K9/00 ,  A61K31/554 ,  A61P25/24

CPC classification number: A61K31/496 ,  A61K9/0053 ,  A61K31/554 ,  A61P25/24

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20240307379A1

公开(公告)日：2024-09-19

申请号：US18670627

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Joshua JORDAN ,  Adam SAVITZ

IPC: A61K31/496 ,  A61B5/16

CPC classification number: A61K31/496 ,  A61B5/165

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20220387424A1

公开(公告)日：2022-12-08

申请号：US17805374

申请日：2022-06-03

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li Shen ,  Vinit Shah ,  Adam Savitz

IPC: A61K31/496 ,  A61P25/24

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

公开(公告)号：US20240197721A1

公开(公告)日：2024-06-20

申请号：US18528486

申请日：2023-12-04

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Josh JORDAN ,  Adam SAVITZ

IPC: A61K31/496 ,  A61B5/16 ,  A61B5/372 ,  A61K9/00 ,  A61K45/06 ,  A61P25/24

CPC classification number: A61K31/496 ,  A61B5/165 ,  A61B5/372 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/24

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20250049738A1

公开(公告)日：2025-02-13

申请号：US18670556

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Adam SAVITZ ,  Joshua JORDAN ,  Maimon ROSE ,  Akshay SUJATHA RAVINDRAN

IPC: A61K31/165 ,  A61K9/00 ,  A61P25/24

Abstract: This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.

公开(公告)号：US20250009738A1

公开(公告)日：2025-01-09

申请号：US18892030

申请日：2024-09-20

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Joshua JORDAN ,  Adam SAVITZ

IPC: A61K31/496 ,  A61B5/16

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20240316016A1

公开(公告)日：2024-09-26

申请号：US18670632

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Wei WU ,  Chao WANG ,  Nicholas COOPER ,  Joshua JORDAN ,  Adam SAVITZ

IPC: A61K31/4402 ,  A61K9/00 ,  A61K45/06 ,  A61P25/28

CPC classification number: A61K31/4402 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/28

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US20240307376A1

公开(公告)日：2024-09-19

申请号：US18670588

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li SHEN ,  Vinit SHAH ,  Adam SAVITZ

IPC: A61K31/496 ,  A61P25/24 ,  G16H20/10

CPC classification number: A61K31/496 ,  A61P25/24 ,  G16H20/10

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

公开(公告)号：US20230117508A1

公开(公告)日：2023-04-20

申请号：US18063907

申请日：2022-12-09

Applicant: ALTO NEUROSCIENCE, INC.

Inventor： Amit ETKIN ,  Dan SEGAL ,  Maria FERREIRA DA SILVA ,  Lauren BLAKE

IPC: A61K31/4468 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/519 ,  A61P25/00

Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic α7 receptor agonist, a β3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).